Accuray Postpones Release of First Quarter Fiscal 2009 Results
Conference Call to be Rescheduled
SUNNYVALE, Calif., Nov. 6 /PRNewswire-FirstCall/ -- Accuray Incorporated
(Nasdaq: ARAY), a global leader in the field of radiosurgery, announced today
that in conjunction with its independent auditors and legal advisors, the
Company is further reviewing financial results for the first quarter of fiscal
2009, ended September 27, 2008.
In response to allegations by a former employee of possible improprieties
in handling and accounting for certain inventory items, the Company has
commenced an internal investigation into the allegations, using an independent
external investigator. The internal investigation is not yet complete, and as
a result the Company is not able to release its financial results for the
fiscal quarter ended September 27, 2008. In addition, the Company will not be
able to file its Quarterly Report on Form 10-Q today, the date on which such
filing is due. The Company expects to file a Notice of Late Filing on Form
12b-25 with the SEC tomorrow.
Upon conclusion of the investigation, Accuray will file its Form 10-Q and
announce first quarter of fiscal 2009 results.
About the CyberKnife(R) Robotic Radiosurgery System
The CyberKnife Robotic Radiosurgery System is the world's only robotic
radiosurgery system designed to treat tumors anywhere in the body
non-invasively. Using continual image guidance technology and computer
controlled robotic mobility, the CyberKnife System automatically tracks,
detects and corrects for tumor and patient movement in real-time throughout
the treatment. This enables the CyberKnife System to deliver high-dose
radiation with pinpoint precision, which minimizes damage to surrounding
healthy tissue and eliminates the need for invasive head or body stabilization
frames.
About Accuray
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is a
global leader in the field of radiosurgery dedicated to providing an improved
quality of life and a non-surgical treatment option for those diagnosed with
cancer. Accuray develops and markets the CyberKnife Robotic Radiosurgery
System, which extends the benefits of radiosurgery to include extracranial
tumors, including those in the spine, lung, prostate, liver and pancreas. To
date, the CyberKnife System has been used to treat more than 50,000 patients
worldwide and currently 145 systems have been installed in leading hospitals
in the Americas, Europe and Asia. For more information, please visit
http://www.accuray.com.
